US · Healthcare · Biotechnology
EPS came in at -0.20 against a street estimate of -0.22 — a beat of 9.1%.
Analysts rate Zura Bio Limited Class A Ordinary Shares a strong buy (7 buy, 0 hold, 0 sell out of 7) with an average price target of $19.00.
| Fund | Stake |
|---|---|
| Suvretta Capital Management, LLC | 9.85% |
| VR Adviser, LLC | 6.72% |
| MPM Oncology Impact Management LP | 4.67% |
| JPMorgan Chase & Co | 4.54% |
| Great Point Partners LLC | 4.40% |
| BRAIDWELL LP | 4.15% |
| Siren, L.L.C. | 3.90% |
| BlackRock Inc | 3.77% |
Technicals, trade setups with a published hit rate, AI analysis and earnings-call summaries for Zura Bio Limited Class A Ordinary Shares — free to start.
Open in the appGoogle PlayApp StoreData updated 2026-11-07.